BamSEC and AlphaSense Join Forces
Learn More

Lixte Biotechnology Holdings Inc. – Material Contracts

NASDAQ: LIXT    
Share price (5/22/26): $5.88    
Market cap (5/22/26): $72.8 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 2 pages Stock Option Cancellation Agreement
12/34/56
EX-10.1
from 8-K 5 pages Restricted Share Unit Award Agreement
12/34/56
EX-10.1
from 8-K 2 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 36 pages Amended and Restated Share Exchange Agreement Among Orbit Capital Inc. Liora Technologies Europe Ltd. and Lixte Biotechnology Holdings, Inc. Effective as of November 21, 2025 Share Exchange Agreement
12/34/56
EX-10.2
from 8-K 20 pages Material contract
12/34/56
EX-10.1
from 8-K 6 pages Material contract
12/34/56
EX-10.1
from 8-K 17 pages Share Exchange Agreement Among Orbit Capital Inc. and Lixte Biotechnology Holdings, Inc. Dated as of December 30, 2025 Share Exchange Agreement
12/34/56
EX-10.2
from 8-K 10 pages Material contract
12/34/56
EX-10.1
from 8-K 6 pages Material contract
12/34/56
EX-10.3
from 8-K 1 page Reference Is Hereby Made to That Certain Royalty Agreement Dated as of November 24, 2025 (The “Royalty Agreement”), Entered Into by and Between Lixte Biotechnology Holdings, Inc., a Delaware Company (The “Company”), and Orbit Capital Inc., a Cayman Islands Corporation (The “Royalty Holder”). the Company and the Royalty Holder Hereby Agree, the Royalty Agreement Is Hereby Deemed Null and Void and of No Further Force or Effect
12/34/56
EX-10.2
from 8-K 11 pages Personal and Confidential Re: | Registered Direct Shelf Takedown | Placement Agent Agreement Dear Mr. Pursglove
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 10 pages Royalty Agreement
12/34/56
EX-10.1
from 8-K 38 pages Share Exchange Agreement Among Orbit Capital Inc. Liora Technologies Europe Ltd. and Lixte Biotechnology Holdings, Inc. Dated as of November 21, 2025 Share Exchange Agreement
12/34/56
EX-10.3
from 10-Q 38 pages Agreement for Gsk & Lixte Supported Collaborative Study
12/34/56
EX-10.2
from 8-K 29 pages Personal and Confidential Mr. Geordan Pursglove, Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, Ca 91101 Re: LIXT | Rd | Placement Agent Agreement Dear Mr. Pursglove
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 26 pages Personal and Confidential Mr. Geordan Pursglove, Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, Ca 91101 Re: LIXT | Pipe | Placement Agent Agreement Dear Mr. Pursglove
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.28
from S-1 15 pages Underwriter Warrant to Purchase Common Stock Lixte Biotechnology Holdings, Inc
12/34/56